Participated · Seed · Sep 2023

Truewind offers a secure generative-AI platform tailored to accounting professionals, used by public accounting firms, in-house accounting teams, and professional service providers. The platform is designed to augment productivity and streamline workflows, and in partnership with customers it absorbs 47% of month-end close tasks. Truewind says its revenue grew fourfold over the past year while working with firms including EisnerAmper and Frank Rimerman. The company will use the new funding to expand its accountant community network, scale its multidisciplinary team, and build out additional product features. Truewind emphasizes security and trust as core elements of its product for handling complex, sensitive work. The company reports having customers and accounting-firm partners across the country who are deploying its generative-AI solutions. Truewind provides an AI-powered bookkeeping and finance back‑office for startups, combining large language models (like GPT) with a concierge service to deliver reliable bookkeeping and detailed financial models. The platform captures business context to interpret financial data and supplies startups with financial models and ongoing accounting support. Truewind intends to transform the finance and accounting industry through automation and AI-assisted workflows. The company was founded by Alex Lee and Tennison Chan in November 2022 and participated in Y Combinator's Winter 2023 batch. Based in San Francisco, Truewind plans to use new capital to accelerate development of its AI-powered bookkeeping and finance platform. In September 2023 the company announced a $3.0M seed raise to fund that roadmap.

Participated · Seed · Dec 2022

Recall.ai offers a unified API that abstracts the complexity of building and scaling meeting and conversation capture across platforms like Zoom, Google Meet, Microsoft Teams, and Slack Huddles. The platform supplies recordings, transcripts, and metadata in near real time (metadata available within 10 seconds after a meeting ends), enabling developers to embed conversation-aware AI features quickly. Recall.ai processes over three terabytes per second of raw video through custom pipelines and launches over eight million EC2 instances monthly to support its infrastructure. The company serves over 2,000 customers, including HubSpot, ClickUp, and Apollo.io, and processes millions of meetings monthly. Product expansion plans include Desktop Recording SDK, dialers, phone, and in-person meeting support, plus additional storage, playback, and agentic AI integrations. Recall.ai is headquartered in San Francisco and positions itself as the infrastructure layer for conversation data across sales, recruiting, healthcare, and productivity applications. Recall.ai provides infrastructure and a unified API that lets companies access raw audio and video from virtual meeting platforms including Google Meet, Microsoft Teams, Slack Huddles and Zoom, plus platforms with no API. Customers use that data to build AI-powered meeting apps such as sales coaching, meeting notetakers and daily standup bots. The company charges per hour of audio and video processed and in less than two years has grown annual revenues from zero to several million dollars, with more than 300 enterprise customers and “millions” of end users. Recall.ai says it is SOC2, GDPR, CCPA and HIPAA compliant, stores recordings for a maximum of seven days and offers an API endpoint for immediate deletion. The startup launched in 2022 and was founded by David Gu and Amanda Zhu, who previously built a real-time transcription tool and integrations for conferencing platforms. Recall.ai currently has nine employees and plans to grow to more than 16 by year-end; the new capital will be used to expand the team and build integrations with more data sources. Recall.ai offers a unified API that accesses meeting data including real-time video and audio, participant identities, speaking times, join/leave events and screen-sharing signals to enable apps across sales, support, hiring, research and more. The API currently integrates with Zoom, Google Meet and Microsoft Team and is being used by about 50 companies while the product remains in private beta. Recall.ai charges customers per minute of audio and video processed and is already generating revenue. The company abstracts away the engineering and infrastructure needed to capture and process meeting streams, saving teams months of integration work and large hosting footprints. Founders David Gu and Amanda Zhu built the product after working on a research tool that produced real-time transcription from meeting recordings. Plans include adding more video conferencing and telephony system integrations as the product expands.

Participated · Seed · Jun 2022

Nue provides a unified Revenue Lifecycle platform that combines CPQ, customer lifecycle management, billing, invoicing, collections, and revenue intelligence in a Salesforce-native architecture. The product enables hybrid monetization models including subscriptions and usage-based consumption, real-time usage rating and billing, and enterprise features like billing account hierarchies. Nue positions itself as an alternative to legacy tools such as Salesforce CPQ and Zuora, emphasizing faster ROI, omnichannel flexibility, and reduced implementation complexity. In 2024 the company delivered three-fold year-over-year sales growth and counts customers including Procurify, Iodine, Mews, and i3 Verticals. Financially, the company has raised a total of $40 million to date. Nue plans to accelerate product innovation, enhance customer success, and expand globally while targeting a major share of the $4 billion CPQ and billing markets over the next three to four years. Nue.io provides a quote-to-revenue platform built on the Salesforce platform, offering pricing, sales, and finance tools. The platform includes automated pricing and quoting, sales enablement tools, financial reporting and analytics, and usage-based billing. Nue positions its product to help SaaS businesses optimize pricing and sales strategies, improve cash flow, and reduce operating costs. Led by CEO Mark Walker, the company plans to use the new funding to expand its product offerings and accelerate growth. Nue.io is based in San Mateo, California. With the latest round, the company has raised a total of $15M. Nue.io, based in San Francisco, offers an omni-channel RevOps platform designed for modern SaaS companies. The platform enables RevOps teams to manage quotes to orders to renewals to billing while delivering accurate, real-time analytics to Finance. Nue supports direct and self-service commerce, innovative pricing models, and streamlined processes to accelerate sales. Led by Tina Kung and Kate McCullough, the company positions itself to help teams innovate and manage customer revenue lifecycles end-to-end. Nue closed a $6m seed round to further develop its platform and analytics capabilities. The funding is intended to expand its end-to-end revenue lifecycle management and real-time analytics functionality.

Participated · Series B · Jun 2021

Zenflow, led by CEO Shreya Mehta, is a South San Francisco-based medical device company developing a minimally invasive treatment for urinary obstruction caused by benign prostatic hyperplasia (BPH). Its core product, the investigational Spring® System, uses a small spring-like coil to gently prop open the urethra while preserving natural anatomy. The Spring® System is an investigational device and is not approved for commercial sale. Zenflow intends to use the funds from its recent financing for a Pre-Market Approval (PMA) submission and to prepare for commercialization upon FDA approval. The company’s clinical research program covers over 300 patients across multiple studies, including the pivotal BREEZE™ prospective, multicenter, controlled study of more than 200 patients. Financially, Zenflow closed a $24M Series C financing to support its regulatory and commercialization efforts. Zenflow, Inc. is a South San Francisco-based medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate (BPH). Its lead product, the Spring® System, is intended as a minimally invasive treatment option for patients with debilitating BPH symptoms. The company plans to use the new funding to support a pivotal clinical trial and pursue FDA clearance of the Spring® System. Zenflow is led by Co-Founder and CEO Nick Damiano. The company announced the appointment of Susan Stimson as President; she brings over 25 years of experience in development and commercialization of medical devices, including senior roles at Intersect ENT. The recent financing positions Zenflow to advance its clinical and regulatory pathway toward commercialization. Zenflow develops the Spring® System, an implantable device intended to treat benign prostatic hyperplasia (BPH). The Spring Implant is composed of super-elastic shape-memory material and is deployed through a small, flexible catheter to enable a less invasive, less painful in-office procedure. The device is currently undergoing clinical trials with leading global urologists and is available for investigational use only in select countries. The company received a $5M credit facility from Square 1 Bank to support short-term and long-term growth initiatives. Founded in 2014 and based in South San Francisco, Zenflow is backed by F-Prime Capital Partners, Invus Opportunities, Medical Technology Venture Partners, Y Combinator and the Stanford-StartX Fund. Zenflow develops the Spring System, a minimally invasive technology that delivers a low-profile superelastic implant into the prostatic urethra to permanently relieve BPH symptoms in a single procedure with fast recovery and minimal side effects. Founded in 2014 out of the Stanford Biodesign Innovation Fellowship and based in San Francisco, the company initiated a first-in-human ZEST safety and feasibility study in 2016. Zenflow has received grant funding from the NIH and NSF and was one of the first medical device companies funded by Y Combinator; it has also been supported by StartX and the Rosenman Institute. The company closed a $31.4M Series A equity financing led by Invus Opportunities, F-Prime Capital Partners, and Medical Technology Venture Partners. Proceeds will be used to perform additional clinical studies to further validate safety and effectiveness and to prepare for commercial launch. Zenflow anticipates enrolling patients in the UK, Australia, New Zealand, and Mexico in 2018 while pursuing an IDE from the FDA to initiate a pivotal U.S. trial.

Participated · Series D · May 2021

Emboline is a privately held medical device company focusing on minimizing embolic complications during structural heart interventions. Its lead product, the Emboliner® Embolic Protection System, captures and removes embolic debris released during transcatheter aortic valve replacement and similar procedures, aiming to provide both cerebral and systemic protection. The company recently completed enrollment of the PROTECT H2H IDE clinical trial assessing the Emboliner and plans to present trial data at the American College of Cardiology Annual Scientific Session on March 29, 2026. With an extensive intellectual-property portfolio covering full-body embolic filtration and aortic deflection, Emboline is positioning itself as a comprehensive embolic-protection platform provider. The firm is now preparing regulatory submissions and expects to launch commercially in the United States and Europe later in 2026. Proceeds from its latest financing will fund these commercialization efforts and continued product development. The Emboliner remains investigational and is not yet available for sale, and no revenue or user metrics have been publicly disclosed.